HIMS climbs nearly 4% after buyers return despite ongoing FTC and law firm investigations

Traders Union
All News
Stocks
Hims & hers surges 3.64% today

Highlights

The Federal Trade Commission filed a lawsuit against Hims & Hers Health, putting the company under regulatory scrutiny.
Kaplan Fox law firm began investigating possible securities law violations related to the actions of Hims & Hers Health.
Hims & Hers Health stock trades with bullish momentum above key support levels, showing a 57% probability of an upward move within a $28.72 to $35.7 range.

Regulatory scrutiny intensifies as lawsuit drives legal investigation

Hims & Hers Health stock experienced heightened scrutiny after the Federal Trade Commission initiated a lawsuit against the company. The legal action prompted the Kaplan Fox law firm to begin an investigation into possible securities law violations connected to Hims & Hers Health. Market participants are closely tracking these developments for their potential regulatory and reputational implications.

Anton Kharitonov, expert at Traders Union, sees persistent legal headwinds weighing on Hims & Hers Health despite its recent price recovery. He notes that FTC actions and the ongoing law firm probe introduce regulatory uncertainty, dampening the fundamental outlook. Weak alignment among momentum indicators and the overbought signal in intraday action cast doubts on the sustainability of the uptrend. Technical support at $32.08 is fragile if negative sentiment re-ignites. "Investors should remain cautious given unresolved legal risks and mixed signals from momentum indicators," Kharitonov asserts.

Viktoras Karapetjanc, expert at Traders Union, views the 3.64% surge and bullish alignment across moving averages as signs of market resilience. He believes that, despite the regulatory headlines, strong demand and technical positioning point to sustained investor confidence. Karapetjanc expects supportive action near $32.08 and sees a breakout above $32.45 as a catalyst for rally continuation. The constructive momentum suggests further growth potential. "The bullish structure remains intact and any move beyond resistance could unlock new upside for Hims & Hers Health," he states.

Parshwa Turakhiya, analyst, highlights the recent gap up and the stock's position near the top of its daily range. He observes mixed technical signals, with some momentum indicators urging caution while short-term buyer strength persists. Turakhiya focuses on the immediate trading range, viewing $32.08 as a near-term pivot for tactical moves. "Traders should watch for a clean break from this range to catch the next sentiment-driven swing," he advises.

Mixed momentum signals as technical support faces volatility

Hims & Hers Health is trading above its 20-day, 50-day, and 200-day moving averages ($29.9, $32.08, and $28.83, respectively), which highlights bullish momentum across short-, medium-, and long-term timeframes. The price remains above the Ichimoku Kijun ($30.05), with immediate technical support near the 50-day average ($32.08) and resistance at today's intraday high ($32.45), consistent with a bullish MA-50 vs MA-200 alignment. Momentum indicators present a mixed outlook: the MACD and ADX are neutral, the RSI at 50.82 and CCI both point to a buy setup, while the Stochastic RSI signals a strong sell. Bull/Bear Power shows intraday buyer dominance with an overbought reading, but the Awesome Oscillator does not confirm a bullish bias. The stock gapped up by about $1.37 (4.41%) and is trading near the top of its $30.34 – $32.45 daily range, with volatility at 6.95%. This combination suggests persistent upward pressure, yet some indicator conflict signals possible short-term caution.

Earlier, analysts noted that Hims & Hers Health faced heightened legal and regulatory risks, which had introduced downside pressure to its technical outlook. The current setup, featuring a confirmed move above key moving averages and persistent volatility, puts particular focus on whether the price can sustain levels above $32.45 to maintain the bullish structure in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.